select a format

Single User License
USD 2000 INR 129580
Site License
USD 4000 INR 259160
Corporate User License
USD 6000 INR 388740

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Tinea pedis (Athlete Foot)-Pipeline Review, H2 2016

Tinea pedis (Athlete Foot)-Pipeline Review, H2 2016


  • Products Id :- GMDHC8894IDB
  • |
  • Pages: 50
  • |
  • December 2016
  • |
  • |
  Request for Sample Report

Executive Summary

Tinea pedis (Athlete Foot)-Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tinea pedis (Athlete Foot)-Pipeline Review, H2 2016, provides an overview of the Tinea pedis (Athlete Foot) (Infectious Disease) pipeline landscape.

Athlete's foot, also known as tinea pedis, is a common foot infection caused by fungi called dermatophytes. Symptoms include dry flaking skin on the soles of the feet, unpleasant foot odour and small itchy bubbles or blisters on the soles of the feet. Treatment includes antifungal medicines.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Tinea pedis (Athlete Foot)-Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Tinea pedis (Athlete Foot) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Tinea pedis (Athlete Foot) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Tinea pedis (Athlete Foot) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 1, 3 and 1 respectively.

Tinea pedis (Athlete Foot) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Tinea pedis (Athlete Foot) (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Tinea pedis (Athlete Foot) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Tinea pedis (Athlete Foot) (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Tinea pedis (Athlete Foot) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Tinea pedis (Athlete Foot) (Infectious Disease)

Reasons to Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Tinea pedis (Athlete Foot) (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Tinea pedis (Athlete Foot) (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Tinea pedis (Athlete Foot) Overview 6

Therapeutics Development 7

Pipeline Products for Tinea pedis (Athlete Foot)-Overview 7

Tinea pedis (Athlete Foot)-Therapeutics under Development by Companies 8

Tinea pedis (Athlete Foot)-Pipeline Products Glance 9

Late Stage Products 9

Clinical Stage Products 10

Early Stage Products 11

Tinea pedis (Athlete Foot)-Products under Development by Companies 12

Tinea pedis (Athlete Foot)-Companies Involved in Therapeutics Development 13

Anacor Pharmaceuticals Inc 13

Astellas Pharma Inc 14

Biolab Farmaceutica Ltda 15

Blueberry Therapeutics Ltd 16

Dermala Inc 17

Helix BioMedix Inc 18

Novan Inc 19

Novoteris LLC 20

Sol-Gel Technologies Ltd 21

Viamet Pharmaceuticals Inc 22

Tinea pedis (Athlete Foot)-Therapeutics Assessment 23

Assessment by Monotherapy Products 23

Assessment by Target 24

Assessment by Mechanism of Action 26

Assessment by Route of Administration 28

Assessment by Molecule Type 30

Drug Profiles 32

AN-2718-Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

AS-2077715-Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

BB-2603-Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

dapaconazole-Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Drug for Athlete's Foot-Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

E-06-Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

HB-1275-Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

nitric oxide-Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

SB-208-Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

VT-1161-Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

Tinea pedis (Athlete Foot)-Dormant Projects 45

Tinea pedis (Athlete Foot)-Product Development Milestones 46

Featured News & Press Releases 46

Jul 21, 2016: Novan Announces First Patient Dosed in Phase 2 Anti-Fungal Program 46

Jul 15, 2015: Viamet to Present at American Podiatric Medical Association 2015 Annual Scientific Meeting 46

Jul 09, 2014: Viamet Reports Additional Positive Interim Results of Phase 2 Studies of VT-1161 with Moderate to Severe Interdigital Tinea Pedis 47

Mar 12, 2014: Viamet Reports Positive Interim Results of Phase 2 Interdigital Tinea Pedis Study of VT-1161 47

Appendix 49

Methodology 49

Coverage 49

Secondary Research 49

Primary Research 49

Expert Panel Validation 49

Contact Us 49

Disclaimer 50

List of Figures

Number of Products under Development for Tinea pedis (Athlete Foot), H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Clinical Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Assessment by Monotherapy Products, H2 2016 23

Number of Products by Targets, H2 2016 24

Number of Products by Stage and Targets, H2 2016 24

Number of Products by Mechanism of Actions, H2 2016 26

Number of Products by Stage and Mechanism of Actions, H2 2016 26

Number of Products by Routes of Administration, H2 2016 28

Number of Products by Stage and Routes of Administration, H2 2016 28

Number of Products by Molecule Types, H2 2016 30

Number of Products by Stage and Molecule Types, H2 2016 30

List of Tables

Number of Products under Development for Tinea pedis (Athlete Foot), H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Late Stage Development, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 10

Comparative Analysis by Early Stage Development, H2 2016 11

Products under Development by Companies, H2 2016 12

Tinea pedis (Athlete Foot)-Pipeline by Anacor Pharmaceuticals Inc, H2 2016 13

Tinea pedis (Athlete Foot)-Pipeline by Astellas Pharma Inc, H2 2016 14

Tinea pedis (Athlete Foot)-Pipeline by Biolab Farmaceutica Ltda, H2 2016 15

Tinea pedis (Athlete Foot)-Pipeline by Blueberry Therapeutics Ltd, H2 2016 16

Tinea pedis (Athlete Foot)-Pipeline by Dermala Inc, H2 2016 17

Tinea pedis (Athlete Foot)-Pipeline by Helix BioMedix Inc, H2 2016 18

Tinea pedis (Athlete Foot)-Pipeline by Novan Inc, H2 2016 19

Tinea pedis (Athlete Foot)-Pipeline by Novoteris LLC, H2 2016 20

Tinea pedis (Athlete Foot)-Pipeline by Sol-Gel Technologies Ltd, H2 2016 21

Tinea pedis (Athlete Foot)-Pipeline by Viamet Pharmaceuticals Inc, H2 2016 22

Assessment by Monotherapy Products, H2 2016 23

Number of Products by Stage and Target, H2 2016 25

Number of Products by Stage and Mechanism of Action, H2 2016 27

Number of Products by Stage and Route of Administration, H2 2016 29

Number of Products by Stage and Molecule Type, H2 2016 31

Tinea pedis (Athlete Foot)-Dormant Projects, H2 2016 45

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Anacor Pharmaceuticals Inc, Astellas Pharma Inc, Biolab Farmaceutica Ltda, Blueberry Therapeutics Ltd, Dermala Inc, Helix BioMedix Inc, Novan Inc, Novoteris LLC, Sol-Gel Technologies Ltd, Viamet Pharmaceuticals Inc

Tinea pedis (Athlete Foot) Therapeutic Products under Development, Key Players in Tinea pedis (Athlete Foot) Therapeutics, Tinea pedis (Athlete Foot) Pipeline Overview, Tinea pedis (Athlete Foot) Pipeline, Tinea pedis (Athlete Foot) Pipeline Assessment


Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com